Literature DB >> 17339869

The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.

E Lévesque1, R Delage, M-O Benoit-Biancamano, P Caron, O Bernard, F Couture, C Guillemette.   

Abstract

We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs). This study enrolled 17 healthy volunteers with no polymorphisms (controls) and 17 carriers of UGT1A9 -275/-2152 selected among 305 individuals genetically screened for UDP-glucuronosyltransferase (UGT) polymorphisms. Additional investigative groups included carriers of UGT1A8*2 (A173G) (n=9), UGT1A8*3 (C277Y) (n=4), and UGT1A9*3 (M33T) (n=5). Genetic analysis also included UGT2B7 to detect UGT2B7*2 (His268Tyr) and the promoter haplotype -1248A>G, -1241T>C, -1054T>C, -842G>A, -268A>G, -102T>C. Kinetics were measured in plasma and urine after a single 1.5 g oral dose of MMF, by high-performance liquid chromatography coupled with tandem mass spectrometry, over 12 h after drug intake. Compared to controls, MPA exposure was significantly lower for UGT1A9 -275/-2152 carriers, with no significant changes in MPAG. The estimates of enterohepatic (re)cycling (area under the concentration-time curve (AUC6-12 h/AUC0-12 h)) were significantly lower for MPA, MPAG, and AcMPAG in UGT1A9 -275/-2152 subjects. Compared with controls, UGT1A9*3 carriers had higher MPA and AcMPAG exposure, whereas homozygosity for the UGT1A8*2 allele and heterozygosity for UGT1A8*3 allele had no impact on MPA PKs. Compared with UGT2B7*1/*1 individuals (n=10), UGT2B7*2/*2 subjects (n=17) presented significantly higher free MPA C(max) values and elevated free and total MPA. Results indicate that after a single oral dose of MMF in healthy volunteers, specific UGT genotypes significantly alter MPA PKs and this clearly warrants additional studies with complete and detailed genetic profiling of UGT1A8, UGT1A9, and UGT2B7 genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339869     DOI: 10.1038/sj.clpt.6100073

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  42 in total

1.  Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Håvard Søiland; Jennifer Gjerde; Jens Peter Garne; Carol L Rosenberg; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

2.  Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Melanie S Joy; Tandrea Hilliard; Yichun Hu; Susan L Hogan; Jinzhao Wang; Ronald J Falk; Philip C Smith
Journal:  Ann Pharmacother       Date:  2009-06-02       Impact factor: 3.154

3.  UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans.

Authors:  Hugo Girard; Lesley M Butler; Lyne Villeneuve; Robert C Millikan; Rashmi Sinha; Robert S Sandler; Chantal Guillemette
Journal:  Mutat Res       Date:  2008-07-16       Impact factor: 2.433

Review 4.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

Review 5.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

6.  Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer.

Authors:  Dongfang Tang; Yu C Zhao; Hongliang Liu; Sheng Luo; Jeffrey M Clarke; Carolyn Glass; Li Su; Sipeng Shen; David C Christiani; Wen Gao; Qingyi Wei
Journal:  Int J Cancer       Date:  2020-03-09       Impact factor: 7.396

7.  Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach.

Authors:  Ioannis Papageorgiou; Michael H Court
Journal:  Biochem Pharmacol       Date:  2017-04-19       Impact factor: 5.858

8.  Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.

Authors:  L'aurelle A Johnson; William S Oetting; Saonli Basu; Susie Prausa; Arthur Matas; Pamala A Jacobson
Journal:  Eur J Clin Pharmacol       Date:  2008-06-21       Impact factor: 2.953

9.  Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme.

Authors:  Laurent Grosse; Anne-Sophie Campeau; Sarah Caron; Frédéric-Alexandre Morin; Kim Meunier; Jocelyn Trottier; Patrick Caron; Mélanie Verreault; Olivier Barbier
Journal:  Basic Clin Pharmacol Toxicol       Date:  2013-05-20       Impact factor: 4.080

Review 10.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.